Meta-analysis of long-term studies to assess the effect of acarbose on cardiovascular risk reduction - Scientifically credible: Reply [2]

European Heart Journal

Volumn 25, Issue 13, 2004, Pages 1179-1180

  Hanefeld, M G ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DATA BASE; HEART INFARCTION; HUMAN; LETTER; MEDICAL LITERATURE; META ANALYSIS; PRIORITY JOURNAL; RISK REDUCTION; STATISTICAL ANALYSIS;

EID: 3042537819     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ehj.2004.01.027     Document Type: Letter

References (5)

1. Melander H., Ahlquist-Rastadt J., Meijer G., et al. Evidence b(i)ased medicine-selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ. 326:2003;1171-1173
2. CPMP/EWP/2330/99 Points to Consider on Application with (1) Meta-analyses and (2) One Pivotal study (adopted by CPMP May 2001). Available from: http://www.emea.eu.int/pdfs/human/ewp/23099en.pdf
3. Senn S. Statistical aspects of research done outside pharmaceutical industry could be improved. BMJ. 316:1998;228
4. Kübler J. Validity and interpretation of meta-analyses and one pivotal study. DIJ. 35:2001;1507-1515
5. Chiasson J.L., Josse R.G., Gomis R., Hanefeld M., Karasik A., Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. The STOP-NIDDM Trial. JAMA. 290:2003;486-494